Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Yudai Fujiwara"'
Autor:
Hidekatsu Kuroda, Yudai Fujiwara, Tamami Abe, Tomoaki Nagasawa, Takuma Oguri, Sachiyo Noguchi, Naohisa Kamiyama, Yasuhiro Takikawa
Publikováno v:
PLoS ONE, Vol 16, Iss 4, p e0249493 (2021)
Background and aimsWe investigated the usefulness of combining two-dimensional shear wave elastography and the ultrasound-guided attenuation parameter for assessing the risk of progressive non-alcoholic steatohepatitis, defined as non-alcoholic steat
Externí odkaz:
https://doaj.org/article/6fa1f79e9a8c41c6a212e4eda3ef99e5
Autor:
Hidekatsu Kuroda, Tomoaki Nagasawa, Yudai Fujiwara, Hiroki Sato, Tamami Abe, Yohei Kooka, Kei Endo, Takayoshi Oikawa, Kei Sawara, Yasuhiro Takikawa
Publikováno v:
Cancers, Vol 13, Iss 6, p 1295 (2021)
There is limited information regarding the oncological benefits of microwave ablation using ThermosphereTM technology for hepatocellular carcinoma. This study compared the overall survival and recurrence-free survival outcomes among patients with hep
Externí odkaz:
https://doaj.org/article/1c0f683db39144b7ac6128041ca8f7f5
Autor:
Kei Endo, Hidekatsu Kuroda, Jo Kanazawa, Takuro Sato, Yudai Fujiwara, Tamami Abe, Hiroki Sato, Youhei Kooka, Takayoshi Oikawa, Kei Sawara, Yasuhiro Takikawa
Publikováno v:
Cancers, Vol 12, Iss 8, p 2146 (2020)
Although sarcopenia is characterized by a loss of muscle strength and skeletal muscle mass, few studies have evaluated the effect of muscle strength on hepatocellular carcinoma (HCC) patients. We evaluated the impact of sarcopenia-related factors (gr
Externí odkaz:
https://doaj.org/article/825ec3b980574111a4bd34f2a5ee7512
Publikováno v:
Biochemical and Biophysical Research Communications. 666:101-106
Autor:
Yudai Fujiwara, Keisuke Kakisaka, Tomoaki Nagasawa, Yasuhiro Takikawa, Tamami Abe, Hidekatsu Kuroda, Yuji Suzuki
Publikováno v:
Hepatology (Baltimore, Md.)
Background and Aims Acute liver failure (ALF) is a rare but dramatic clinical syndrome characterized by massive hepatic necrosis leading to multiorgan failure. It is difficult to predict the outcomes in patients with ALF using existing prognostic mod
Autor:
Yudai Fujiwara, Kazuyuki Suzuki, Makoto Eizuka, Yasuhiro Takikawa, Manami Miura, Yuki Watanabe, Hiroshi Takahashi, Kenji Yusa
Publikováno v:
Internal Medicine
The patient was a 65-year-old man with alcoholic liver cirrhosis who had been admitted to hospital 5 times for repeated and recurrent overt hepatic encephalopathy (HE) despite numerous therapies, including disaccharide, branched-chain amino acid (BCA
Publikováno v:
International Journal of Automation Technology. 14:625-632
The medical and bio-engineering fields have been increasingly using information and communication technology. To introduce robots into surgical procedures, data on surgical operations are required. Several studies have tried the creation of data on l
Publikováno v:
Journal of medical ultrasonics (2001). 48(4)
The purpose of this study was to evaluate the diagnostic accuracy of the ultrasound-guided attenuation parameter (UGAP) using the LOGEQ E10 for hepatic steatosis in non-alcoholic fatty liver disease (NAFLD) patients and directly compare UGAP with att
Autor:
Kei Sawara, Takayoshi Oikawa, Tamami Abe, Yudai Fujiwara, Kei Endo, Hiroki Sato, Hidekatsu Kuorda, Okamoto Takuya, Yasuhiro Takikawa, Miki Yonezawa
Publikováno v:
World Journal of Gastroenterology
Background Lenvatinib is one of the first-line tyrosine kinase inhibitors used for unresectable hepatocellular carcinoma (HCC). In the present study, we evaluated the potential of early changes in the time-intensity curve (TIC) of arterial phase on
Autor:
Miki Yonezawa, Kazuyuki Ishida, Yasuhiro Takikawa, Yuji Suzuki, Hidekatsu Kuroda, Tamotsu Sugai, Yudai Fujiwara, Tamami Abe, Keisuke Kakisaka
Publikováno v:
Journal of Gastroenterology = Journal of Gastroenterology. 53(12):1285-1291
The prevalence of non-alcoholic fatty liver disease (NAFLD) has increased. Non-alcoholic steatohepatitis (NASH) shows progression of liver fibrosis in NAFLD. It remains unclear which patients with NAFLD will show progression of liver fibrosis. Theref